New hope for kids with AML: gentler chemo combos under trial
NCT ID NCT07059975
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing two new chemotherapy combinations for children and young adults with acute myeloid leukemia (AML) who are at intermediate or high risk of relapse. The goal is to see if these combinations are tolerable and can achieve similar or better survival with fewer long-term side effects. About 36 participants will receive the new drug combinations and be followed for up to three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Idarubicin, fludarabine, cytarabine, venetoclax, etoposide
What this could lead to
If successful, this could lead to a more tolerable chemotherapy regimen for children with AML, potentially reducing long-term side effects while maintaining or improving survival.
What could go wrong
This is a very early, small pilot trial with only 36 participants, so results may not apply to all patients. The new combinations could still cause serious side effects or fail to control the leukemia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Cancer and Hematology Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••